New Antibiotics Study Results from Institute for Clinical Pharmacodynamics Inc. Described (Population Pharmacokinetic Analyses for Sulbactam-durlobactam Using Phase 1, 2, and 3 Data).

A recent study conducted by the Institute for Clinical Pharmacodynamics Inc. focused on population pharmacokinetic analyses for sulbactam-durlobactam, a beta-lactam/beta-lactamase inhibitor combination used to treat certain bacterial infections. The study involved data from eight Phase 1-3 studies and developed a robust model for the plasma pharmacokinetics of the drugs. The research highlighted the impact of factors such as renal function on drug clearance and penetration into specific body compartments. The findings are expected to aid in model-based simulations and understanding pharmacokinetic-pharmacodynamic relationships. [Extracted from the article]